|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Investments at fair value | ||||||||||||||||
| Non-controlled/non-affiliate investments | ||||||||||||||||
| Non-controlled/affiliate investments | ||||||||||||||||
| Controlled affiliate investments | ||||||||||||||||
| Total investments at fair value | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Foreign cash (cost of $14,632 and $2,477, respectively) | ||||||||||||||||
| Restricted cash and cash equivalents | ||||||||||||||||
| Collateral on derivatives | ||||||||||||||||
| Deferred financing costs | ||||||||||||||||
| Interest receivable on investments | ||||||||||||||||
| Interest rate swap | ||||||||||||||||
| Receivable for sales and paydowns of investments | ||||||||||||||||
| Prepaid insurance | ||||||||||||||||
| Unrealized appreciation on forward currency exchange contracts | ||||||||||||||||
| Dividend receivable | ||||||||||||||||
| Total Assets | ||||||||||||||||
| Liabilities | ||||||||||||||||
| Debt (net of unamortized debt issuance costs of $15,936 and $10,110, respectively) | ||||||||||||||||
| Interest rate swap | ||||||||||||||||
| Interest payable | ||||||||||||||||
| Payable for investments purchased | ||||||||||||||||
| Collateral payable on derivatives | ||||||||||||||||
| Unrealized depreciation on forward currency exchange contracts | ||||||||||||||||
| Base management fee payable | ||||||||||||||||
| Incentive fee payable | ||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||
| Distributions payable | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Net Assets | ||||||||||||||||
| Common stock, par value $0.001 per share, 100,000,000,000 and 100,000,000,000 shares authorized, 64,868,507 and 64,868,507 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||
| Paid in capital in excess of par value | ||||||||||||||||
| Total distributable loss | ||||||||||||||||
| Total Net Assets | ||||||||||||||||
| Total Liabilities and Total Net Assets | ||||||||||||||||
| Net asset value per share | ||||||||||||||||
Loading...
